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Secretory Leukocyte Protease Inhibitor (SLPI) is a serine protease inhibitor produced by epithelial and myeloid cells with anti-
inflammatory properties. Research has shown that SLPI exerts its anti-inflammatory activity by directly binding to NF-𝜅B DNA
binding sites and, in so doing, prevents binding and subsequent transcription of proinflammatory gene expression. In the current
study, we demonstrate that SLPI can inhibit TNF-𝛼-induced apoptosis in U937 cells and peripheral blood monocytes. Specifically,
SLPI inhibits TNF-𝛼-induced caspase-3 activation and DNA degradation associated with apoptosis. We go on to show that this
ability of SLPI to inhibit apoptosis is not dependent on its antiprotease activity as antiprotease deficient variants of SLPI can also
inhibit TNF-𝛼-induced apoptosis. This reduction in monocyte apoptosis may preserve monocyte function during inflammation
resolution and promote infection clearance at mucosal sites.
1. Introduction
Secretory Leukocyte Protease Inhibitor (SLPI) is a small
molecular weight protein with multifunctional properties
including antiprotease, antibacterial, antiviral, and anti-
inflammatory effects [1]. The mature SLPI protein is 11.7 kDa
in length and consists of 107 amino acids which are arranged
in two domains of similar folding, giving SLPI a boomerang
shape [2, 3]. Each domain is homologous to the whey acidic
protein (WAP) four-disulphide core (WFDC) domain [4].
SLPI is constitutively expressed in the majority of mucosal
secretions including nasal, bronchial, salivary, tear, cervical,
and seminal secretions [5–8]. SLPI is produced and secreted
by a number of different cell types including neutrophils and
macrophages and by the epithelial cells that line mucosal
surfaces. The physiological concentration of SLPI in saliva
ranges from 4 to 24 𝜇g/mL [9]. Lung epithelial lining fluid
levels of SLPI can be as high as 10 𝜇g/mL, although SLPI con-
centrations have been found to be higher in upper respiratory
airways than in lower airways [1, 9, 10]. The production of
SLPI in such defense sensitive locations where protection
against pathogen is pivotal reinforces the important role SLPI
plays in innate immune defense.
SLPI inhibits a wide variety of proteases including neu-
trophil elastase (NE), cathepsin G, trypsin, chymotrypsin,
chymase, and tryptase [11]. In addition, research suggests that
SLPI has antimicrobial effects and is capable of inhibiting
both Gram positive (Staphylococcus aureus) and Gram neg-
ative (Escherichia coli) bacterial growth [12, 13] as well as
inhibiting HIV viral replication in monocytic cells [14, 15].
In relation to immunomodulation, Jin et al. have shown that
SLPI expression in macrophages is induced by lipopolysac-
charide (LPS) and suppressed by IFN-𝛾 [16]. SLPI inhib-
ited LPS-induced NF-𝜅B activation in macrophages thereby
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decreasing production of TNF-𝛼 and IL-8 [17]. Ding et al.
showed that SLPI can interfere with uptake of LPS into
macrophages [18]. SLPI has been demonstrated to prevent
the degradation of key regulatory proteins IRAK, I𝜅B𝛼, and
I𝜅B𝛽 in response to LPS and lipoteichoic acid [19–21]. In
addition, SLPI exerts a direct effect by entering the nucleus
and competing with the p65 subunit of NF-𝜅B for binding
to its promoter regions in target genes. Therefore, LPS-
induced binding of p65 to the NF-𝜅B consensus-binding sites
in the promoter regions of these genes is prevented and pro-
duction of proinflammatory factors such as TNF-𝛼 and IL-8
is decreased [17].
To date, there has been very little research in the area of
SLPI’s ability to inhibit apoptosis. One study has shown that
SLPI can inhibit neutrophil apoptosis [22] but themechanism
for this effect is unknown. In this study, we demonstrate that
SLPI can inhibit apoptosis in monocytic cells in a way that
does not depend on the protease inhibition effect of SLPI.
2. Materials and Methods
2.1. Materials. The SLPI mutants Lys72SLPI and Gly72SLPI
[23] were provided by Amgen (Thousand Oaks, Ca, USA).
2.2. Cell Culture. Ethical approval for use of peripheral blood
monocytes (PBMs) from whole blood was given by Beau-
mont Hospital Ethics Committee. Human myelomonocytic
U937 cells were purchased from the American Type Culture
Collection (Manassas, USA). PBMs andU937swere routinely
cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated foetal calf serum (Gibco, Life Technologies),
2mM L-glutamine, and 1% (v/v) penicillin/streptomycin
(PAA laboratories GmbH, Austria). Cells for experiments
were seeded at 5 × 105/mL and were preincubated with SLPI,
oxidised SLPI, or SLPI mutants for 1 hr followed by incuba-
tion with TNF-𝛼 (R&D Systems; 10 ng/mL).
2.3. Caspase Activity Assays. Caspase-3 and caspase-7 activ-
ity was determined using the fluorogenic substrate Ac-Asp-
Glu-Val-Asp-7-amino-4-methylcoumarin (DEVD-AMC;
Enzo Life Sciences LTD, Exeter, UK). Briefly, cells were
centrifuged at 1000×g for 5 minutes at 4∘C and lysed in
lysis buffer (50mM Tris pH 7.5, 150mMNaCl, 5mM EDTA,
and 0.2% Nonidet P-40). The cells were then centrifuged at
17,000×g or 10min at 4∘C. The reaction buffer was 10mM
HEPES (pH7.5), 50mMNaCl, 5mMMgCl
2
, 2.5mM DTT,
and 1mM EDTA. Samples were incubated with substrate (50
𝜇M) and fluorescence (substrate turnover) was determined
by excitation at 360 nm and emission at 460 nm in a 96-well
microplate reader. The rate of substrate hydrolysis was mon-
itored at 37∘C and results were expressed as the change (Δ)
in relative fluorescence units (ΔRFU) over a 60min period.
2.4. Western Blotting. Whole cell extracts were prepared for
Western blotting analysis by lysing cell lines and PBECs
in RIPA buffer (50mm Tris-HCl, pH 7.5, 150mmNaCl, 1%
Nonidet P-40, 0.25% sodium deoxycholate, 1mm EDTA, and
1% Triton X-100) supplemented with PMSF, aprotinin, and
sodium orthovanadate. Total protein concentrations were
determined using theBCAmethod (Pierce BCAAssay, Fisher
Scientific UK, Leicestershire). Denatured samples were sep-
arated by electrophoresis on 12% SDS-polyacrylamide gels,
transferred to nitrocellulose membrane, and probed using
rabbit anti-caspase-3, rabbit anti-caspase-7 (Cell Signalling,
1 : 1000), or rabbit anti-GAPDH (Santa Cruz Biotechnology
Inc., 1 : 1000). Binding was detected using the appropriate
horseradish peroxidase-conjugated secondary antibodies
(Fisher Scientific UK), visualized by chemiluminescence (GE
Healthcare UK, Buckinghamshire), and analysed using the
Syngene G:Box and GeneSnap software (SynGene UK, Cam-
bridge).
2.5. Cell Death ELISA. The cell death ELISA kit (Roche) was
used to quantify apoptosis levels. The ELISA was carried out
according to the manufacturer’s instructions.
2.6. Oxidation of SLPI. Oxidation of SLPI was carried out as
described previously [19].
2.7. Statistical Analysis. All data were analysed using Graph-
Pad Prism 5.0 (GraphPad Software Inc., San Diego, CA) and
are reported as mean ± SEM. Results are representative of at
least 𝑛 = 3 unless otherwise indicated. Means were compared
by unpaired 𝑡-test or one-way analysis of variance (ANOVA)
as appropriate. 𝑝 < 0.05 was accepted to indicate statistical
significance.
3. Results
3.1. SLPI Inhibits TNF-𝛼-Induced Caspase-3 and Caspase-7
Activity in Monocytic Cells. As effector caspases are respon-
sible for most of the physiological changes that occur in
apoptosis, SLPI’s effect on effector caspase-3 and caspase-7
activity was initially investigated using the specific substrate
DEVD-AMC (Figure 1(a)). U937 monocytes treated with
TNF-𝛼 showed an increase in DEVD-AMC activity com-
pared to control cells, indicating upregulation in caspase-3
and caspase-7 activity in response to TNF-𝛼 stimulation. In
comparison to cells treated with TNF-𝛼 alone, a significant
decrease in caspase-3 and caspase-7 activity was observed in
U937 monocytes pretreated with SLPI. This result suggests
that SLPI is having an antiapoptotic effect in TNF-𝛼 treated
monocytes.
3.2. SLPI Inhibits TNF-𝛼-Induced Cell Death in Monocytic
Cells. SLPI’s effect on TNF-𝛼-induced apoptosis was investi-
gated further using a cell death ELISA.Thepresence ofmono-
and oligonucleosomes in the cytoplasm of apoptotic cells is
due to DNA degradation and occurs several hours before the
plasmamembrane breakdown.This assay detects the amount
of mono- and oligonucleosomes in the cytoplasmic fraction
of cell lysates permitting detection of apoptosis. U937 mono-
cytes treated with TNF-𝛼 showed an increase in the amount
of apoptosis as expected which was significantly decreased in
the presence of SLPI (Figure 1(b)). This result is consistent
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Figure 1: Effect of SLPI on TNF-𝛼-induced caspase-3 and caspase-7 activity and cell death. U937monocytic cells were pretreated for 1 hr with
SLPI (10 𝜇g/mL) and stimulated with TNF-𝛼 (10 ng/mL) for 4 hr. (a) Activity of the effector caspases, caspase-3 and caspase-7, was measured
using the fluorogenic substrate DEVD-AMC. Results are representative of 𝑛 = 6. (b)The amount of apoptosis occurring in cells wasmeasured
by ELISA. Results are representative of 𝑛 = 6 experiments. ∗ indicates 𝑝 < 0.05.
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Figure 2: Effect of SLPI on TNF-𝛼-induced caspase-3 and caspase-7
activity in peripheral bloodmonocytes. Peripheral bloodmonocytes
were isolated and pretreated for 1 hr with SLPI (10𝜇g/mL) and
then incubated with TNF-𝛼 (10 ng/mL) for 4 hr. Activity of the
effector caspases, caspase-3 and caspase-7, was measured using the
fluorogenic substrate DEVD-AMC. Results are representative of 𝑛 =
6. ∗ indicates 𝑝 < 0.05.
with previous findings that SLPI has an antiapoptotic effect
on TNF-𝛼 treated monocytes.
3.3. SLPI Inhibits TNF-𝛼-Induced Caspase Activation in
Peripheral Blood Monocytes. To ensure that the results found
in the U937 cell line were physiologically representative of
monocytes, peripheral blood monocytes (PBMs) were iso-
lated and treated with TNF-𝛼 alone and in the presence of
SLPI. PBMs treated with SLPI exhibited a significant reduc-
tion in basal and TNF-𝛼-induced caspase activity (Figure 2).
This suggested that results obtained with the U937 cells were
physiologically relevant.
3.4. The Role of SLPI’s Antiprotease Activity in the Inhibi-
tion of TNF-𝛼-Induced Apoptosis. The effect of antiprotease-
deficient variants of SLPI (Lys72SLPI, Gly72SLPI, and oxi-
dised SLPI) [19, 23] on the inhibition of apoptosis was inves-
tigated. Lys72SLPI, Gly72SLPI, and oxidized SLPI retained
the ability to inhibit TNF-𝛼-induced apoptosis as evidenced
by caspase-3 and caspase-7 activity assays (Figure 3(a)) and
cell death ELISA results (Figure 3(b)). These findings suggest
that the antiapoptotic ability of SLPI is independent of its
antiprotease activity.
3.5. Investigation into SLPI’s Mechanism of Apoptosis Inhibi-
tion. U937 cell lysates were prepared from cells treated with
TNF-𝛼 alone and in the presence of SLPI and levels of active
caspase -3 and caspase-7 investigated by Western blotting.
Despite the fact that there was a decrease in caspase-3 and
caspase-7 activity (Figure 1(a)), active forms of both caspases
were found in cells treated with TNF-𝛼 in the presence of
SLPI as shown in Figure 4. However, the levels of active
caspase-3 appear reduced in cells treated with TNF-𝛼 and
SLPI compared to cells stimulated with TNF-𝛼 alone. To
address the possibility that SLPI may directly inhibit caspase-
3 activity, recombinant caspase-3 was pretreated with a molar
excess of SLPI prior to the addition of DEVD-AMC. As
illustrated in Figure 5, no inhibition of active caspase-3 was
detected.
4. Discussion
SLPI has been shown to inhibit LPS-induced NF-𝜅B acti-
vation by displacing or inhibiting NF-𝜅B binding to its
promoter regions in target genes [17]. As well as inducing
a host of proinflammatory cytokines, NF-𝜅B activation also
leads to the induction of prosurvival factors, which com-
bine to inhibit apoptosis. Therefore, the effect of SLPI on
TNF-𝛼-induced apoptosis was investigated to see if SLPI
4 Journal of Immunology Research
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Figure 3: Effect of SLPI and oxidised SLPI on apoptosis in monocytic cells. U937 cells were pretreated with SLPI (10𝜇g/mL) or oxidised
SLPI (10 𝜇g/mL) and stimulated with TNF-𝛼 (10 ng/mL) for 4 hr. (a) Activity of the effector caspases, caspase-3 and caspase-7, was measured
using the fluorogenic substrate DEVD-AMC. (b) The amount of apoptosis occurring in cells was assessed by ELISA (Roche). Results are
representative of 𝑛 = 3. ∗ indicates 𝑝 < 0.05.
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Figure 4: Effect of SLPI on active caspase-3 and caspase-7 pro-
tein levels. U937 cells were pretreated with SLPI (10𝜇g/mL) and
stimulated with TNF-𝛼 (10 ng/mL) for 4 hr. RIPA extracts were
electrophoresed on 10–15% SDS-PAGE gels and analysed byWestern
blotting using anti-caspase-3 and anti-caspase-7 antibodies. The
blots were tripped and reprobed for GAPDH to control for protein
loading. Results are representative of 𝑛 = 3.
was capable of inhibiting NF-𝜅B antiapoptotic effects. We
induced apoptosis using TNF-𝛼 which has previously been
shown to have proapoptotic effects in monocytic cells [24].
Surprisingly, SLPI was shown to downregulate caspase-3 and
caspase-7 activity and inhibit TNF-𝛼-induced apoptosis in
monocytes. This effect was further investigated using the cell
death ELISA which confirmed that SLPI inhibited TNF-𝛼-
induced cell death.
Both NE and cathepsin G have previously been shown to
play a role in apoptosis [25, 26]. Therefore, we hypothesised
that, as a serine protease inhibitor, SLPI inhibits apoptosis
via NE or cathepsin G inhibition. To test this, we eval-
uated antiprotease deficient variants of SLPI (Lys72SLPI,
Gly72SLPI, and oxidised SLPI) [19, 23].The antiprotease inac-
tive forms of SLPI retained the ability of inhibiting TNF-𝛼-
induced apoptosis suggesting that SLPI’s antiapoptotic effects
were not mediated by its antiprotease activity. In relation to
SLPI’s anti-inflammatory activity, the literature is conflicting
regarding the role that SLPI’s antiprotease function plays in
mediating these effects [27, 28].
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Figure 5: Effect of SLPI on recombinant caspase-3 activity. SLPI
(100 ng) was pretreated for 1 hr with recombinant human caspase-
3 (10 ng). Caspase-3 activity was measured using the fluorogenic
substrate DEVD-AMC. Results are representative of 𝑛 = 5.
In a bid to understand how SLPI may mediate its anti-
apoptotic activity, the effect of SLPI on other components
of the apoptotic pathway was then investigated. Similar to
SLPI, PR39 is a small, highly cationic, and antimicrobial pep-
tide which can also enter cells and inhibit apoptosis. PR39
achieves this through the upregulation of the antiapoptotic
protein IAP-2 [29]. IAP-2 and other IAP family members
inhibit caspase-3 and caspase-7 activity.We therefore hypoth-
esised that SLPI could act in a similar manner to PR39 by
upregulating IAP family members which could inhibit
caspase-3 and caspase-7 directly. We looked at the effect of
SLPI on IAP-1, IAP-2, survivin, and XIAP protein levels but
found that SLPI did not upregulate any of these factors (data
not shown). In addition, SLPI was unable to directly inhibit
recombinant caspase-3 activity. However, as the levels of
active caspase-3 appear lower in cells treated with TNF-𝛼 and
SLPI compared to cells stimulated with TNF-𝛼 alone, it is
Journal of Immunology Research 5
possible that at least part of SLPI’s antiapoptotic mechanism
may involve inhibition of the generation of active caspase-3
from its inactive zymogen perhaps via inhibition of upstream
initiator caspases such as caspase-8. Further work is required
to elucidate the exact mechanism by which SLPI exerts its
antiapoptotic effects in response to TNF-𝛼. Previouswork has
reported the ability of SLPI to limit TNF-𝛼-induced hydrogen
peroxide production by human neutrophils [27, 30]; there-
fore, it is also possible that SLPI may be able to interfere with
more upstream TNF-𝛼 signalling intermediates.
From a physiological standpoint, SLPI’s antiapoptotic
effect in monocytes may be important for optimising the
removal of dying cells and bacteria as part of the inflamma-
tion resolution process and the fight against infection. Con-
ditions such as emphysema and cystic fibrosis, characterised
where SLPI levels are altered by degradation [10, 31] in the
lung, are dominated by a chronic inflammatory response,
excessive apoptosis, and infection. Therefore, SLPI’s role in
controlling this process on the respiratory tract may be an
important homeostatic mechanism in maintaining sufficient
monocyte numbers for infection and inflammation resolu-
tion. More work is needed to determine the mechanism by
which SLPI alters apoptotic pathways.
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